Loading...
Therapeutic cancer vaccines and combination immunotherapies involving vaccination
Recent US Food and Drug Administration approvals of Provenge(®) (sipuleucel-T) as the first cell-based cancer therapeutic factor and ipilimumab (Yervoy(®)/anticytotoxic T-lymphocyte antigen-4) as the first “checkpoint blocker” highlight recent advances in cancer immunotherapy. Positive results of th...
Na minha lista:
| Udgivet i: | Immunotargets Ther |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2014
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4918241/ https://ncbi.nlm.nih.gov/pubmed/27471705 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/ITT.S40264 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|